Yuan Q.Song L.-W.CHUN-JEN LIULi Z.Liu P.-G.Huang C.-H.Yan Y.Ge S.-X.Wang Y.-B.Peng C.-Y.Zhang J.JIA-HORNG KAODING-SHINN CHENPEI-JER CHENXia N.-S.2021-07-032021-07-0320130017-5749https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984569897&doi=10.1136%2fgutjnl-2012-302656&partnerID=40&md5=4f764b4ce84604fa9f9b38c8d15bca1fhttps://scholars.lib.ntu.edu.tw/handle/123456789/568473[SDGs]SDG3adefovir dipivoxil; biological marker; hepatitis B core antibody; hepatitis B surface antibody; hepatitis B surface antigen; hepatitis B(e) antigen; peginterferon alpha2a; antibody blood level; chronic hepatitis; drug response; hepatitis B; human; immune response; immunoassay; letter; predictive value; priority journal; prognosis; quantitative analysis; seroconversionletter10.1136/gutjnl-2012-302656226986512-s2.0-84984569897